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Objectives. The purpose of this prospective randomized study
was to compare the electrophysiologle effects of conventional and
high dose loading regimens of amiodarone in patients with sus-
tained ventricular tachyeardia.
Background. Uncontrolled studies in which patients have beer
treated with an oral loading dose of 2 to 4 g/day of atniodarone
have suggested that, compared with a conventional loading dose,
this dosing regimen results in more rapid control of spontaneous
ventricular tachycardia and ventricular tachycardia induced by
programmed stimulation
.
Methods. Patients in whom sustained monomorphic ventricu
.
lar tachycardia was inducible by programmed stimulation and
who were refractory to class I autiarrhythmic medications were
randomly assigned to receive either a conventional (n = 15) or a
high (n = 17) loading dose of amiodarone . The conventional dose
consisted of 600 mg twice a day for 10 days . The high dose regimen
consisted of 50 mg/kg body weight per day on days 1 to 3,
30 mg/kg per day on days 4 and 5 and 600 mg twice a day on days
6 to 10 . An electrophysiologic t- ' performed in the baseline
state and after 3 and 10 days of then : :)y . An adequate response to
amlodarone was defined as the inability to induce ventricular
tachycardia or the ability to induce only relatively slow (cycle
length L,350 ms) hemodynamically stable ventricular tachycardia .
The conventional loading dose of amiodarone has consisted
of l to 1 .4 glday for 10 to 14 days (1-12) . Recent uncontrolled
studies (13-15) have suggested that larger oral doses of 2 to
4 g/day of amiodarone may be effective in controlling spon-
taneous ventricular arrhythmias and ventricular tachycardia
induced by programmed stimulation after only 2 to 3 days of
therapy . However, no studies have prospectively compared
the electrophysiologic or therapeutic effects of these large
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Results. After 3 days of therapy, 2 of 14 patients who receiv
the conventional loading dose and 6 of 15 patients who received
the high dose loading regimen had an adequate response to
amiodarone (p = 0.08). After 10 days of therapy, four patients in
each group had an adequate response to amiodarone (p = NS) .
Three patients who received the high dose and one patient who
received the conventional dose of amiodarone had an adequate
response after 3 days of therapy but not after 10 days of therapy .
There were significant increases in the sinus cycle length, atrio .
ventricular block cycle length, ventricular effective refractory
period and ventricular tachyeardi2 cycle length after 3 and 10
days of therapy compared with baseline values regardless of the
dosing regimen . The extent of the effects of amlodarone on these
variables after 3 and 10 days of therapy was similar with both
dosing regimens.
Conclusions. The therapeutic and elecirophysiologic effects of
conventional and high dose loading regimens of andodarone do
not differ significantly after 3 or 10 days of therapy . High oral
loading doses of amiodarone do not offer any significant clinical
advantage over a conventional loading dose of amlodarone for
controlling ventricular tachycardia induced by programmed stim-
ulation .
(J Am Coll Cardiol 1993,22 .1723-9)
doses of amiodarone with those of a conventional loading
regimen. Therefore, the purpose of this study was to com-
pare, in a randomized fashion, the electrophysiologic effects
of conventional and high dose loading regimens of amio-
darone in patients undergoing electrophysiologic testing
because of sustained ventricular tachycardia .
Methods
Patient selection . Thirty-two patients with sustained
monomorphic ventricular tachycardia inducible by pro-
grammed stimulation who were unsuccessfully treated with
class I antiarrhythmic medications and who were candidates
for amiodarone therapy were randomly assigned to receive
either a conventional (n = 15) or high (n = 17) dose loading
0735-1097193/S6.00
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Table 1 . Patient Characteristics
Values presented arc mean value ± SD or number of p atients . LV a NA
ventricular: VT - ventricular tachycardia .
regimen under a protocol approved by the University of
Michigan Institutional Review Board . Two patients in the
high dose group were withdrawn from the study after 2 days
r ' treatment because of severe nausea or the onset of
symptomatic bradycardia. The characteristics of the 30
patients who remained in the study are described in Table 1 .
AM= dosing regimess. The conventional loading
dose consisted of 600 mg twice a day for 10 days . This dosing
regimen was used because it is typical of the loading doses
used in prior studies (1,4-12) and these studies have dem-
onstrated that this is an effective dosing regimen for control-
ling ventricular tachycardia induced by programmed stimu-
lation. The high dose regimen consisted of 50 mg/k& body
weight per day on days 1 to 3, 30 mg/kg per day on days 4
and 5 and M mg twice a day from day 6 to It This dosing
regimen was used because a recent study (15) using the same
regimen demonstrated control of ventricular tachycardia
induced by programmed stimulation in <3 days. The mean
(±SD) total loading dose of amiodarone in the patients who
received the high dose regimen was 23 .3 ± 2.6 g compared
with 12 g in the patients who received the conventional
loading dose. All patients were hospitalized during the
10-day loading period and underwent continuous telemetric
electrocardiographic (ECG) monitoring . They were ques-
tioned daily regarding side effects of amiodarone .
Ekctreph~ testing. Each patient underwent a
baseline electrophysiologic test after providing informed
consent and after discontinuation of all antiarrhythmic
agents for L-5 half-lives. An electrophysiologic test was
repeated after 3 and 10 days of therapy with amiodarone. In
the conventional dose group, 14 patients underwent the day
3 electrophysiologic test and 14 patients underwent the day
10 test; I patient in the conventional dose group refused the
day 3 test and another developed pneumonia after 8 days of
therapy and did not undergo a follow-up test until 2 weeks
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later. All 15 patients in the high dose group underwent both
the 3- and 10-day follow-up electrophysiologic tests .
Quadripolar electrode catheters were inserted into a
femoral vein and positioned in the high right atrium, His
bundle position and right ventricular apex . Leads V,, 1, 11
and III and the intracardiac electrograms were displayed on
an oscilloscope and recorded at a paper speed of 25 to
100 mmls on a Mingograph 7 recorder (Siemens-Elema) .
Pacing was performed at twice diastolic threshold with a
pulse duration of 2 ms using a programmable stimulator
(Bloom Associates), In all patients, the capture threshold
was <1 mA .
During electrophysiologic testing, the atrioventricular
(AV) block cycle length was determined by incremental
atrial pacing in steps of 10 ms . The ventricular effective
refractory period was measured at the right ventricular apex
using basic drive cycle lengths of 400 and 0) ms . The right
atrium and ventricle were paced simultaneously using an
8-beat drive train and a 4-s intertrain pause . A 1-min condi-
tioning train was used before the refractory periods were
measured. The effective refractory period was measured by
scanning diastole after each 8-beat drive train with a single
ventricular extrastimulus . The coupling interval of the ex-
trastimulus was shortened in 10-ms steps until there was loss
of capture, and then lengthened in 2-ms steps until ventric-
ular capture occurred . The effective refractory period was
defined as the longest coupling interval that did not result in
ventricular capture. A prior study (16) demonstrated that
this technique for determination of the ventricular effective
refractory period results in measurements that are reproduc-
ible to within 4 ms .
The stimulation protocol used to induce ventricular
tachycardia has been described in detail previously (17) .
Programmed stimulation was initially performed at the right
ventricular apex . One to three extrastimuli were delivered
after an 8-beat drive train using a basic drive cycle length of
350 ms, then 400 and 600 ms . If ventricular tachycardia was
not induced, the stimulation protocol was repeated at the
right ventricular septum or outflow tract . Whenever sus-
tained ventricular tachycardia was induced, a 12-lead ECG
of the ventricular tachycardia was recorded .
Sustained monomorphic ventricular tachycardia was de-
fined as ventricular tachycardia of uniform configuration
lasting >30 s or requiring termination because of cardiovas-
cular collapse. Hemodynamically stable ventricular tachy-
cardia was defined as ventricular tachycardia associated
with a systolic pressure >80 mm Hg and no symptoms of
cerebral hypofusion. An adequate response to afniodarone
was defined as 1) the ability to induce only ventricular
tachycardia that had a cycle length X350 ms and was
hemodynamically stable (9,18), or 2) as the inability to
induce ventricular tachycardia (5,8,10) . The end points of
the stimulation protocol were induction of hemodynamically
unstable, sustained monomorphic ventricular tachycardia,
repeated induction of only hemodynamically stable, sus-
tained monomorphic ventricular tachycardia or completion
Conventional
Loading
Dose
(n = 15)
High Dose
Loading
Regimen
(n = IS)
p
Value
Age (yr)
0 ± 8 67 ± 9 0 .2
A ejection fraction 0.29 ± 0.10 0 .35 ± 0 .14 0.2
Men/women 12/3 1510
0.2
Prior antiarrhythmic trials (no .) 1 .4 ± 0.7 1 .5 ± 0 .9 0.8
Heart disease 0,6
Coronary artery disease 13 14
Idiopathic dilated cardiomyopathy I
Valvutar Mode of presentation 0 .9
Aborted sudden death 4
Syncope 4
Sustained monomorphic VT 6
Nonsustained V'r 2 1
of the pacing protocol at two right ventricular sites . Plasma
amiodarone and desethylarniodarone concentrations were
measured on completion of each of the follow-up electro-
physiologic tests .
Statistical analysis . Comparisons of continuous variables
were performed either by using the Student unpaired t test or
by analysis of variance (ANOVA) with repeated measures,
as appropriate . Multiple comparisons after ANOVA were
performed using the post-hoc Scheff6 F test. Categoric
variables were compared by contingency table analysis . A
p value < 0.05 was considered significant .
Results
Effects on ventricular tachycardia, inducibility and cycle
length (Table 2). All patients had inducible, hemodynami-
cally unstable, sustained monomorphic ventricular tachycar-
dia in the baseline state . After 3 days of therapy, 2 (14%) of
14 patients who received the conventional dose of amio-
darone had an adequate response compared with 6 (40%) of
15 patients who received the high dose regimen (p = 0 .08) .
After 10 days of therapy, four patients in each group had an
adequate response to therapy (p = NS) . One of the two
patients treated with the conventional dose and three of the
six patients treated with the high dose of amiodarone dem-
*p < 0.05 versus conventional dose baseline value. t p < 0.0.', versus high dose baseline value
. +p < 0 .05 versus conventional
dose baseline and day 3 values,
Values presented are mean value ± SD or number of patients, VT = ventricular tachycardia
.
onstrated an adequate response on day 3 but had inducible
unstable ventricular tachycardia on day 10. Of the I I pa-
tients who received the conventional dose and underwent a
day 10 follow-up clectrophysiologic test after an inadequate
response on day 3, 8 continued to have an inadequate
response and 3 had an adequate response . Of the nine
patients in the high dose group who had an inadequate
response on day 3, eight continued to have an inadequate
response and one had an adequate response on day 10 .
Patients in both the conventional and the high dose group
demonstrated a significant proloikgation over baseline value
in mean ventricular tachycardia cycle length on days 3 and
10 of therapy either when all induced ventricular tachycar-
dias were considered or when only the most rapid of all
induced ventricular tachycardias induced were analyzed
(Table 2). In the conventional dose group, but not in the high
dose group, differences in the mean ventricular tachycardia
cycle lengths between days 3 and 10 were also significant
(Table 2). There were no differences in the mean ventricular
tachycardia cycle length or in the number of induced ven-
tricular tachycardias between the conventional and high
dose groups either at baseline or after 3 or 10 days of therapy
(Table 2)
Electrophysiologic effects (Tables 3 and 4). There were no
differences between the conventional and high dose loading
Table 3. Serial Electrophysiologic Effects of Conventional and High Dose Loading Regimens of Amiodarone
*p < 0 .01 versus day 3 conventional dose ; there were no other significant differences between conventional and high dose therapy at baseline, day 3 or day
10. Values presented are mean value ± SD . AVB = atrioventricular block
; BD = basic drive ; CL = cycle length
; VERP = ventricular effective refractory period .
Baseline Day 3
Day 10
Conventional
High Dose
Conventional High Dose
(n = 15)
Conventional High Dose
(n
	
15)
(n 15) (n 15)
(n 14) (n 14)
Sinus CL (ms)
728 108
768 147 926 214 884 ± 173 926 120
926
136
AVB CL (ms)
382 83 401 79
488 98 504 ± 115 531 114
531 74
VERP
BD CL 400 ms 240 ± 15 234 ± 18 259 ± 18 267 ± 22
273 ± 21 267 ± 21
BD CL Ok ms 255 ± 19 252 ± 21 285 ± 21
288 ± 25 293 ± 15
291 t- 19
Plasma concentration (1kg1ml)
Amiodarone
0.9 ± 0 .4 2 .5 ± 1,9* 1 .4 ± 0.5
1 .4 ± 0 .4
Desethylamiodarone
0.4 ± 0 .2 0 .5 ± 0 .3
0 .7 ± 0.2 0
.7 ± 0 .2
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Table 2
. Serial Effects of Conventional and High Dose Loading Regimens of Amiodarone on the Results of Programmed
Ventricular Stimulation
1725
Baseline
Day 3
Day 10
Conventional
High Dose Conventional
High Dose
(n (n = 14)
(n = 15)
(n = 14)
(n = 15)
No inducible VT
0
0
1 0
Hemodynamically stable VT
0 0
3
4
VTs induced (no.) 1 .3 ± 0.6
1 .5 ± 0 .7 1.6±1 .1
1.3±0.7 I.5±0
.8 1.6±0.9
VT cycle length (ws)
AD inducible VT 266 ± 36 295 ± 57
325 ± 51*
356 ± 70t 354 ± 50t 7,36 ± 56t
Fastest V'r induced
267 ± 40 282 ± 52 305 ± 37*
337 ± 66t
352 ± 55t
:53 ± 60t
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Takile 4. Electrophysiologic Data
: Mean Differences for Paired Follow-Up Data for High and Conventional Dose Amiodarone
armcYcis
Longo
AV Block cycle
L-SM
VERP
am& 400MWM
All values shown are the mean differences between
paired measurements for the variables over time (Student paired
f
test). Negative values indicate a
decrease in the mean differences over time . Abbreviations as in Table 3 .
regimens with respect to the sinus cycle length, AV block
cycle length or ventricular effective refractory periods at
baseline or after 3 or 10 days of therapy. The high dose
loading regimen resulted in a significantly higher plasma
antiodarone concentration on day 3 than did the conven-
tional loading dose, but there was no difference between the
two loading regimens in the plasma desethylamiodarone
concentrations on day 3 or in the amiodarone or desethyla-
miodarone concentrations on day 10 .
There were significant serial changes over time in the
sinus cycle length, AV block cycle length and ventricular
refractory periods in both the conventional and high dose
groups (Table 4) . In the conventional dose group, compari-
son of days 3 and 10 with baseline revealed significant
increases in each of the variables measured (Fig. 1). In
contrast, the only variable that increased significantly from
day 3 to day 10 in this group was the ventricular effective
refractory period measured using a basic drive cycle length
of 400 ms. In the high dose group, comparison of day 10 with
Film I . Serial electrophysiologic effects of a conventional loading
dose of amiodarone in 15 patients, Ban represent the mean value
and I SD, For each variable, comparisons that were not significant
am not shown . AV - atrioventricular ; BDCL = basic drive cycle
length; VERP - ventricular effective refractory period .
"X~
\N
'\\7
X,
X
1 ;
VERP
MUM=
baseline revealed significant increases in all variables mea-
sured (Fig. 2). Comparison of day 3 with baseline showed
significant increases in AV block cycle length and ventricu-
lar effective refractory periods (Fig. 2). There were no
significant differences in the high dose group between days 3
and 10 of therapy in any variable measured .
Side effects. There was no difference in the incidence of
side effects reported by the patients who received the
conventional and high dose regimens . Three (20%) of the 15
patients who received the conventional dose of amiodarone
had side effects that did not require a dosage reduction ; the
side effects consisted of nausea, weakness or dizziness .
Similarly, 4 (27%) of the 15 patients who received the high
dose loading regimen of amiodarone reported side effects of
either nausea, dizziness or weakness .
Discussion
Major findings . The major finding of this study is that a
high dose oral loading regimen of amiodarone does not offer
Figure 2 . Serial electrophysiologic effects of a high dose loading
regimen of amiodarone in IS patients . Bars represent the mean value
and I SD. For each variable, comparisons that were not significant
are not shown. Abbreviations as in Figure 1 .
Sinus Cycle
Length
AV Block Cycle
Length
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VERP
6;'[H.400ms
VERP
BDCL600ms
Day 0 Versus Day 3
Day 0 Versus Day 10 Day 3 Versus Day 10
p p
p
Value
p p
Conventional Value High
p
Value
Conventional Value
High Value Conventional High Value
Sinus CL
175 0 .02 104 0.1
18)
* 0.01 158 < 0 .01 21 0.6 55 0 .2
AH interval -2 .7 0 .7 10.4 0.7
15 .4 0.01 -2.9
0.8
20 0.02 -18
0.4
HV interval 6.2 0 .06 13 .1 < 0
.01 8.5 0.01 6.4 0.1 2 .9 0.3 -7 .5
0.1
AVB CL 109
< 0 .01 95 < 0.01 160 * 0.01 125 < 0.01 41 < 0 .01 28 0.2
VERP at 400 ms 19 < 0 .01 33 < 0
.01
35 * 0.01
34 < 0.01 18
0 .03 1 0.9
VERP at 600 ms 31 < 0 .01
37 < 0,01 41 * 0.01 38 < 0.01 11 NS
2 0.8
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any significant advantage over conventional loading regi-
mens of amiodarone for controlling ventricular tachycardia
induced by programmed stimulation . There were no signifi-
cant differences between the conventional and high dose
loading regimens after 3 or 10 days of therapy with respect to
the number of patients who had an adequate response to
amiodarone. In addition, there were no significant differ-
ences in the electrophysiologic effects of the two dosing
regimens after either 3 or 10 days of therapy . In accord with
the larger amount of amiodarone used, the mean plasma
concentration of amiodarone after 3 days of therapy was
more than twice as high in the high dose group as in the
conventional dose group (2 .5 vs. 0.9 mg/liter) . Therefore,
although rapid attainment of a high plasma antiodarone
concentration is possible with the high dose loading regimen,
this does not translate to more pronounced electrophysio-
logic effects compared with those of a conventional loading
regimen of amiodarone .
Comparison of day 3 and day 10 therapeutic end points .
An adequate response to amiodarone at 3 days of therapy
was not predictive of an adequate response after 10 days of
therapy . Fifty percent of the patients treated with either the
conventional or the high dose regimen who had an adequate
response on day 3 had inducible, hemodynamically unstable
ventricular tachycardia on day 10 . For the high dose group,
this result differs from the findings of Evans et al . (15), who
used the same loading regimen as in the present study . In
that study, two of the three patients who had no inducible
ventricular tachycardia after I day of therapy continued to
have no inducible ventricular tachycardia at follow-up .
Therefore, Evans et al . (15) concluded that the high dose
regimen may allow for a shorter loading period and earlier
discharge from the hospital . The differing results of the
present study and those of Evans et al
. (15) may be attrib-
utable to the use of different programmed stimulation proto-
cols, differing intervals at which testing was performed
(3 and 10 days in our study versus I and 5 days in the study
by Evans et al.), or to a random difference related to small
sample sizes .
Although our study did not find that an adequate response
to amiodarone during electropharmacologic testing after 3
days of therapy was predictive of an adequate response after
10 days of therapy, the inducibility of hemodynamically
unstable ventricular tachycardia after 3 days of high dose
therapy appeared to be predictive of an inadequate response
after 10 days of therapy. It is possible that an electrophysi-
ologic test after 3 days of high dose therapy may be useful in
the early identification of drug nonresponders, who then
could be offered an alternative form of therapy early in their
hospital stay . Additional studies with larger numbers of
patients will be necessary to address this possibility
.
Effects of amiodarone on ventricular tachycardia cycle
length . In both the conventional and the high dose group,
there was a significant prolongation in mean ventricular
tachycardia cycle length at 3 and 10 days of therapy com-
pared with baseline
. In the conventional dose group, but not
KALBFLEISCH ET AL
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in the high dose group, the mean ventricular tachycardia
cycle length was also longer significantly after 10 days than
after 3 days of therapy . These results indicate that in the
conventional dose group, the effects on ventricular tachy-
cardia cycle length from baseline to 10 days of therapy are
more gradual than in the high dose group, where. the majority
of the effect occurs by day 3 . Using the same high dose
regimen as in the present study, Evans et al . (15) also found
that most of the effects of amiodarone on ventricular tachy-
cardia cycle length occurred by day I of therapy, with no
significant change between day 5 and Jay I of therapy
.
Serial electrophysiologic effects of amiodarone
. The two
dosing regimens we tested resulted in significant prolonga-
tion of the sinus cycle length, ventricular effective refractory
period and AV block cycle length when comparing 10 days
of therapy with baseline values . These results are in agree-
ment with those of other studies (1-12) that evaluated the
electrophysiologic effects of amiodarone after 10 to 14 days
of therapy .
In our study, in both the conventional and the high dose
group, the majority of the short-term effects of amiodarone
on the sinus node, AV conduction and ventricular refracto-
riness occurred within the I st 3 days of therapy . In a prior
study (15) that used the same high dose loading regimen used
in the present study, electrophysiologic testing was per-
formed after I day, 5 days and 6 weeks of therapy . A
significant Lengthening of ventricular refractoriness was
found to have occurred after only I day of therapy, with no
additional lengthening after 5 days of therapy . As in the
present study, this indicated that most of the early electro-
physiologic effects of a high dose loading regimen of amio-
darone may occur within I to 3 days .
We believe that the present study is the first in which the
clectrophysiologic effects of a conventional loading dose of
amiodarone were measured after <10 days of therapy and
therefore is the first to demonstrate that the majority of the
short-term electrophysiologic effects of amiodarone occur
after only 3 days of therapy even when a conventional
loading regimen is used . For example, in a prior study (11) in
which the serial effects of a conventional loading regimen of
amiodarone were measured, some of the electrophysiologic
effects of amiodarone weree maximal after 2 weeks of ther-
apy; however, no testing was performed before 2 weeks of
therapy .
Although no previous studies measured the electrophys-
iologic effects of a conventional loading regimen of amio-
darone earlier than 10 days after the onset of therapy, a prior
study (19) did assess the early serial beta-adrenergic antag-
onistic effects of a conventional loading regimen
. In accord
with our results, the majority of the early sympatholytic
effects of amiodarone occurred by 2 days of therapy
.
Side effects . Overall, the high dose oral amiodarone reg-
imen was fairly well tolerated . Only 2 of the 17 patients who
received this regimen required a reduction in dosage because
of side effects. Evans et al. (15) similarly reported that high
dose amiodarone was well tolerated in 15 of their 16 patients
.
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In our study, a similar proportion of patients who received
the conventional and high dose regimens had side effects that
did not require a reduction in dosage
.
y is implications
. Our results demonstrate
that the therapeutic and electrophysiologic effects of con-
ventional and high dose loading regimens of amiodarone do
not differ significantly, even though the high dose regimen
results in a significantly greater plasma amiodarone concen-
tration by 3 days .
A possible explanation for this observation in that the
early effects of amiodarone are related to the myocardial
concentration of the drug and that the kinetics of amiodarone
transfer from the central compartment to the myocardium
are saturated at plasma concentrations obtained with a
conventional loading regimen . Our results also demonstrate
that the majority of the short-term electrophysiologic effects
of amiod ne occur within the 1st 3 days of therapy with
both dosing regimens. The long-term electrophysiologic ef-
fects of amiodarone, which may take up to 10 weeks to
stabilize (11), may be due to incremental myocardial accu-
mulation of amiodarone, gradual accumulation of the active
metabolite desethylamiodarone (20-22), the gradual effects
of amiodarone on the thyroid axis (23,24), a combination of
these three effects or some other as yet undescribed effect .
Comparison with previous studies. A previous study (25)
compared two dosing regimens of amiodarone (1 .2 day for
14 days and 2 .4 glday for 7 days) and found no difference
between these two loading regimens with respect to their
therapeutic or electrophysiologic effects . These results im-
plied that the higher dose loading regimen might allow for
earlier discharge of patients from the hospital, However, the
two dosing regimens were compared at different points in
time, Given the results of the present study, it is likely that
no significant differences between the two loading regimens
used in the prior study would have been found had they been
compared at the same points in time .
In tly is . Previous studies
(2631) have demonstrated that intravenously administered
amiodarone may be useful in suppressing ventricular tachy-
cardia within I or 2 days . However, the present results,
which showed no difference between the electrophysiologic
effects of conventional and high dose oral amiodarone ther-
apy despite a much higher amiodarone plasma concentration
after 3 days of high dose therapy, imply that the early
electrophysiologic effects of intravenously administered
amiodarone may not be more pronounced than the effects of
orally administered amiod ne . Consistent with this possi-
bility are the findings of Levine et al . (31), who evaluated the
therapeutic effects of three different intravenous dosing
regimens of amiodarone and found no significant difference
in the efficacy of the lowest and highest doses used
. Whether
a prospective comparison of orally and intravenously admin-
istered amiodarone will demonstrate any significant differ-
ences in the magnitude of therapeutic or electrophysiologic
effects remains to be determined
.
Limitations of the study . The percent of patients who had
an adequate therapeutic response to amiodarone after 3 days
of therapy was 40% in the high dose group compared with
14% in the conventional dose group . Although this difference
was not statistically significant, it is possible that the ten-
dency toward greater efficacy of the high dose regimen on
day 3 might have become significant with larger sample
sizes. In any case, after 10 days of therapy the efficacy of the
two dosing regimens was similar ; therefore, a higher efficacy
at 3 days in the high dose group would have been unlikely to
provide any subsequent clinical advantage
.
Only one high dose loading regimen was tested in this study ;
therefore, a possible advantage of other h' dose loading
regimens cannot be ruled out . The high dose regimen used in
the present study was selected because it had been previously
demonstrated to be well tolerated and efficacious (15) .
A third limitation of the present study is that the thera-
peutic effects of amiodarone on ventricular tachycardia were
assessed only by electropharmacologic testing . Prior studies
(13,14) have indicated that high dose oral loading regimens of
amiodarone may be effective in rapidly suppressing sponta-
neous episodes of ventricular tachycardia . Whether high
dose loading regimens of amiodarone provide an advantage
over a conventional loading regimen in suppressing sponta-
neous episodes of ventricular tachycardia remains to be
determined .
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